About AFT Pharmaceuticals
AFT Pharmaceuticals is a 100% privately owned pharmaceutical company operating in Australia and New Zealand with full development, regulatory and sales/marketing operations.
In addition to distributing agency lines, AFT owns a significant portfolio of IP (trademarks, patents) and product licenses. AFT markets patented, branded & generic drugs and is also involved in drug development.
1998 – started in NZ with first sales made
2000 – acquired shareholdings in 2 South African Pharmaceutical Companies and a wholesaler
2002 – acquired first AFT wholly owned products
2004 – started Australian company and exited South Africa Investment
2004 – started drug development work and filed first 2 global patents
2005 - started first Australian sales
2006 – JV drug development agreement with an EU based company
2008 – Secured an outlicensing deal for 3 AFT products in SE Asia. Dec08, first launches in Malaysia
2009 – Global licensing negotiations for key development project
2009 – Launch of world first combination analgesic - Maxigesic – into New Zealand
2012 - R&D spend increased to $4 million per annum
2012 - Distribution and outlicensing agreements expanded to include 42 countries
2012 - Group Sales to exceeded $50 million per annum
2012 - Started AFT Pharmaceuticals in Singapore and Malaysia, Started AFT Orphan
2013 - Regulatory filings in over 30 countries around the world
Our objective is to build a significant Australasian Pharmaceutical company which is also involved in drug development.
Email email@example.com | New Zealand Freephone 0800-423823